Ravinder N. Maini
Sir Ravinder Nath Maini ( born November 17, 1937 in Ludhiana, India) is a British immunologist and rheumatologist Indian descent. He is known primarily for his work, which led to the development of a new class of drugs, the anti-TNF agents.
Life
Ravinder Nath Maini is the son of Sir Amar Nath Maini (1911-1999), a liberal- conservative British politician of Indian descent in Uganda (then a British colony ), and the first mayor of the city of Kampala and Saheli Maini, née Mehra. He spent his childhood in Africa, finished school in England but from.
Maini acquired at Sidney Sussex College, University of Cambridge with a Bachelor of Science and then graduated in medicine. After working at various hospitals in London (Guy 's Hospital, Brompton Hospital, Charing Cross Hospital ) 1962-1970, he was until 1976 a senior physician (Consultant ) at St. Stephen 's Hospital, also in London.
1979 Maini was director of clinical immunology at the Charing Cross and Westminster Medical School (now Imperial College London) and at the Kennedy Institute of Rheumatology ( KIR ), 1981 he was appointed professor of immunology and rheumatology. In 1990 he was scientific director at KIR; August 2000 to September 2002, he headed the Institute as part of its merger with Imperial College London. His successor at the KIR was Marc Feldmann. From November 2002 until his retirement from clinical practice in 2007 was in London Honorary Consultant Physician Emeritus Maini at Charing Cross Hospital and Hammersmith Hospitals Trust. Since November 2002 he is Emeritus Professor of Rheumatology at Imperial College London.
Maini is married to his second wife. From the first marriage came four children, of whom one son died as a teenager. From the second marriage two children come.
Work
In the late 1960s Maini worked at Dudley Dumonde to messengers that are secreted by lymphocytes.
The work of Maini and his long-time research partner Marc Feldmann dealt with cytokines that are involved in processes of immunity and inflammation, in particular the molecular basis of rheumatoid arthritis. In this case, they both use cell cultures which have been obtained from the patient ( in vitro), as well as experimental animals of model ( in vivo). Together with Fionula M. Brennan, they identified TNF- α (tumor necrosis factor ) as a key cytokine. Today it is known that TNF among other things, the inflammation and tissue destruction in rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis (Bechterew's disease ), Crohn's disease and ulcerative colitis controls. Maini and Feldmann operated translational medicine: they developed the hypothesis that blockade of TNF can inhibit inflammation, this hypothesis is verified in the laboratory, verified in practice and ultimately guided the studies that led to the approval of the first representative of the new group of medications called TNF blockers (today, these include several monoclonal antibodies and a fusion protein ) by the competent authorities in Europe and the United States led.
Other works focus on the blockade of other cytokines, including IL -6 and IL- 17th
Writings (selection )
- Immunology of Rheumatic Diseases, 1977
- Modulation of Autoimmune Disesae (ed. ), 1981
- Textbook of the Rheumatic Diseases ( co-author ), 1986
- T -Cell Activation in Health and Disease (ed. ), 1989
- Rheumatoid arthritis (ed. ), 1992
- Oxford Textbook of Rheumatology ( co-author ), 1993
- Rheumatology ( co-author ), 1993
- Manual of Biological Markers of Disease ( co-author ), 1993-1996
- Oxford Textbook of Medicine ( co-author ), 2001